Edulis Therapeutics is developing a bioresorbable, endoscopically delivered drug depot designed to provide sustained, localized therapy for chronic GI conditions such as stricturing Crohn’s disease.
The platform functions like a “drug-eluting stent for the GI tract,” allowing gastroenterologists to place a biodegradable implant during routine endoscopy that releases medication directly at the disease site over time. By targeting therapy locally, the company aims to reduce systemic drug exposure while potentially delaying or preventing interventions such as balloon dilation, stricturoplasty, or surgery.
Fresh off winning both the AGA and DDW Shark Tank competitions, Edulis is advancing through preclinical studies and exploring broader applications beyond Crohn’s disease, including colorectal cancer, microbiome engineering, and obesity treatment.